Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML)
NCT05744739Phase 1Terminated
- Sponsor
- Northwestern University
- Start
- Sep 2023
- Primary completion
- Jul 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of tomivosertib in acute myeloid leukemia (AML), sponsored by Northwestern University. Primary endpoint: Maximum Pharmacologic Activity at 28 days. Started Sep 2023; status: terminated.
02
Drugs
tomivosertib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05744739.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05744739.